Multi‐institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity
- 25 June 2020
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 122 (5) , 877-883
Abstract
Background/Objectives: Oligometastatic sarcoma pulmonary metastases (PM's) are traditionally treated with resection and/or chemotherapy. We hypothesize that stereotactic body radiotherapy (SBRT) is an effective, safe alternative to surgery that can achieve excellent local control (LC) with a favorable toxicity profile.Methods: Patients treated with SBRT for sarcoma PM's from 2011 to 2016 at Massachusetts General Hospital and the University of Pennsylvania were included. Median dose was 50 Gy. Patients underwent computed tomography (CT) or positron emission tomography/CT Q3 months post‐SBRT.Results: 44 patients with 56 separate PM's were treated with SBRT. Median age was 59 (range 19‐82). 82% received prior chemotherapy, 66% had prior pulmonary resections (range, 1‐5 resections), and 32% received prior thoracic radiotherapy. Median lesion size was 2.0 cm (range, 0.5‐8.1 cm). Median follow‐up was 16 months and 25 months for patients alive at last follow‐up. Overall survival at 12 and 24 months was 74% (95% confidence interval [CI], 67%‐81%) and 46% (95% CI, 38%‐55%). LC at 12 and 24 months was 96% (95% CI, 93%‐98%) and 90% (95% CI, 84%‐96%). LC and overall survival did not differ based on age, gender, histology, fractionation, lesion location, or size (P > .05). Three developed Common Terminology Criteria for Adverse Events version 4 grade‐2 chest‐wall toxicities; one had grade‐2 pneumonitis.Conclusions: In the first multi‐institutional series on SBRT for sarcoma PM's, SBRT has excellent LC and is well‐tolerated. SBRT should be considered as an alternative/complement to resection.Keywords
This publication has 30 references indexed in Scilit:
- Safety and Efficacy of Stereotactic Body Radiation Therapy in the Treatment of Pulmonary Metastases from High Grade SarcomaSarcoma, 2013
- Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non–Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Impact of Introducing Stereotactic Lung Radiotherapy for Elderly Patients With Stage I Non–Small-Cell Lung Cancer: A Population-Based Time-Trend AnalysisJournal of Clinical Oncology, 2010
- Stereotactic Radiotherapy for Pulmonary Oligometastases: A Systematic ReviewJournal of Thoracic Oncology, 2010
- Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung CancerJAMA, 2010
- Outcomes After Stereotactic Lung Radiotherapy or Wedge Resection for Stage I Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Resection of Pulmonary and Extrapulmonary Sarcomatous Metastases Is Associated With Long-Term SurvivalThe Annals of Thoracic Surgery, 2009
- Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung MetastasesJournal of Clinical Oncology, 2009
- Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma1Journal of the American College of Surgeons, 2000
- Long-term results of lung metastasectomy: Prognostic analyses based on 5206 casesThe Journal of Thoracic and Cardiovascular Surgery, 1997